4-hydroxy-10-benzylidene-10H-anthracen-9-one | 69544-83-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 4-hydroxy-10-benzylidene-10H-anthracen-9-one
• 英文别名: 10-(4-hydroxybenzylidene)anthrone；quinonmethide；10-(4-Hydroxybenzylidene)anthracen-9(10H)-one；10-[(4-hydroxyphenyl)methylidene]anthracen-9-one
• CAS: 69544-83-8
• 化学式: C₂₁H₁₄O₂
• mdl: MFCD01545464
• 分子量: 298.341
• InChiKey: ZIVKLZVCDDETHC-UHFFFAOYSA-N

物化性质

• 熔点：
  190 °C (decomp)
• 沸点：
  475.5±24.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为产物：
  描述：

  蒽酮 在 sodium hydroxide 、 对甲苯磺酸 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 8.0h， 生成 4-hydroxy-10-benzylidene-10H-anthracen-9-one
  参考文献：
  名称：

  Regioselective alkylation of anthrahydroquinone and anthrone in water with quinonemethides and other alkylating agents

  摘要：

  DOI：

  10.1021/jo00340a006

文献信息

• 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy
  作者：Josefine Reber、Stephanie Haller、Christopher P. Leamon、Cristina Müller

  DOI：10.1158/1535-7163.mct-13-0422-t

  日期：2013.11.1

  Targeted radionuclide therapy has shown impressive results for the palliative treatment of several types of cancer diseases. The folate receptor has been identified as specifically associated with a variety of frequent tumor types. Therefore, it is an attractive target for the development of new radionuclide therapies using folate-based radioconjugates. Previously, we found that pemetrexed (PMX) has a favorable effect in reducing undesired renal uptake of radiofolates. Moreover, PMX also acts as a chemotherapeutic and radiosensitizing agent on tumors. Thus, the aim of our study was to investigate the combined application of PMX and the therapeutic radiofolate 177Lu-EC0800. Determination of the combination index (CI) revealed a synergistic inhibitory effect of 177Lu-EC0800 and PMX on the viability of folate receptor–positive cervical (KB) and ovarian (IGROV-1) cancer cells in vitro (CI < 0.8). In an in vivo study, tumor-bearing mice were treated with 177Lu-EC0800 (20 MBq) and a subtherapeutic (0.4 mg) or therapeutic amount (1.6 mg) of PMX. Application of 177Lu-EC0800 with PMXther resulted in a two- to four-fold enhanced tumor growth delay and a prolonged survival of KB and IGROV-1 tumor-bearing mice, as compared to the combination with PMXsubther or untreated control mice. PMXsubther protected the kidneys from undesired side effects of 177Lu-EC0800 (20 MBq) by reducing the absorbed radiation dose. Intact kidney function was shown by determination of plasma parameters and quantitative single-photon emission computed tomography using 99mTc-DMSA. Our results confirmed the anticipated dual role of PMX. Its unique features resulted in an improved antitumor effect of folate-based radionuclide therapy and prevented undesired radio-nephrotoxicity. Mol Cancer Ther; 12(11); 2436–45. ©2013 AACR.

  摘要 靶向放射性核素疗法在几种癌症的姑息治疗方面取得了令人瞩目的成果。叶酸受体已被确认与多种常见肿瘤类型特别相关。因此，它是利用基于叶酸的放射性缀合物开发新型放射性核素疗法的一个有吸引力的靶点。此前，我们发现培美曲塞（PMX）在减少肾脏对放射性叶酸的摄取方面具有良好的效果。此外，培美曲塞（PMX）还是一种肿瘤化疗和放射增敏剂。因此，我们的研究旨在探讨 PMX 和治疗性放射性酚 177Lu-EC0800 的联合应用。组合指数（CI）的测定显示，177Lu-EC0800 和 PMX 对叶酸受体阳性的宫颈癌（KB）和卵巢癌（IGROV-1）细胞在体外的活力有协同抑制作用（CI < 0.8）。在一项体内研究中，用 177Lu-EC0800（20 MBq）和亚治疗量（0.4 毫克）或治疗量（1.6 毫克）的 PMX 对携带肿瘤的小鼠进行治疗。与联合使用 PMXsubther 或未经处理的对照组小鼠相比，使用 177Lu-EC0800 和 PMXther 可使 KB 和 IGROV-1 肿瘤小鼠的肿瘤生长延缓率提高 2 至 4 倍，存活时间延长。PMXsubther 通过减少吸收的辐射剂量，保护肾脏免受 177Lu-EC0800（20 MBq）不良副作用的影响。通过测定血浆参数和使用 99mTc-DMSA 进行定量单光子发射计算机断层扫描显示了肾脏功能完好。我们的研究结果证实了 PMX 预期的双重作用。它的独特功能提高了以叶酸为基础的放射性核素疗法的抗肿瘤效果，并防止了不必要的放射性肾毒性。Mol Cancer Ther; 12(11); 2436-45。©2013 AACR。
• Novel Benzylidene-9(10<i>H</i>)-anthracenones as Highly Active Antimicrotubule Agents. Synthesis, Antiproliferative Activity, and Inhibition of Tubulin Polymerization
  作者：Helge Prinz、Yukihito Ishii、Takeo Hirano、Thomas Stoiber、Juan A. Camacho Gomez、Peter Schmidt、Heiko Düssmann、Angelika M. Burger、Jochen H. M. Prehn、Eckhard G. Günther、Eberhard Unger、Kazuo Umezawa

  DOI：10.1021/jm0307685

  日期：2003.7.1

  compounds such as colchicine, podophyllotoxin, and nocodazole. In general, the antiproliferative activity correlated with inhibition of tubulin polymerization. The most active compounds strongly displaced [(3)H]colchicine from its binding site in the tubulin, yielding IC(50) values 3- to 4-fold lower than that of colchicine. The novel benzylidene-9(10H)-anthracenones described in the present study constitute

  合成了一系列新的10-亚苄基-9（10H）-蒽酮和10-（苯甲基）-9（10H）-蒽酮，并在基于K562白血病细胞的试验中评估了其抗增殖活性。发现3-羟基-4-甲氧基亚苄基类似物9h是活性最高的化合物（IC（50）K562：20 nM）。还考虑了构效关系。使用XTT测定法，包括五种抗药性表型，针对五种肿瘤细胞系测试了高活性化合物9h和2,4-二甲氧基-3-羟基亚苄基类似物9l。使用碘化丙啶在单层测定中确定了多种肿瘤细胞系中细胞死亡的诱导。值得注意的是，与长春碱处理过的细胞相似，该系列中的所有化合物均可在K562细胞中诱导伸长。铅化合物9h对K562细胞生长的影响与G2 / M中的细胞周期停滞有关。测定在用9h和9l处理后停在G2 / M中的50％KB / HeLa细胞的浓度，发现其在0.2μM的范围内。此外，我们监测了9h处理的K562细胞和MCF-7 / Casp-3细胞中剂量依赖性ca
• Synthesis and antitumor activity of 10-substituted benzylidene anthrone
  作者：Weixiao Hu、Wei Zhou

  DOI：10.1016/j.bmcl.2003.11.053

  日期：2004.2

  Fifteen compounds of 10-substituted benzylidene anthrone were prepared with moderate yield by reaction of anthrone and substituted benzaldehydes under the presence of pyridine and piperidine as catalyst. Their antitumor activities in vitro were evaluated. The results show that the electron-withdrawing substitutes decrease the activities, the electron-donor substitutes increase the activities; the compound

  在吡啶和哌啶作为催化剂的存在下，通过蒽酮和取代的苯甲醛的反应，以中等收率制备了15种10-取代的亚苄基蒽酮。评价了它们的体外抗肿瘤活性。结果表明，吸电子代用品降低了活性，给电子代用品提高了活性。与邻位或对位取代的化合物相比，具有相同取代基但位于间位的化合物具有更强的活性。有六种化合物显示出对A-549癌细胞生长的强有效抑制作用。这是一种好的领先化合物，值得进一步研究。
• Zhou; Tu; Feng, Journal of Chemical Research - Part S, 2001, # 10, p. 414 - 415
  作者：Zhou、Tu、Feng

  DOI：——

  日期：——
• DIMMEL, D. R.;SHEPART, D., J. ORG. CHEM., 1982, 47, N 1, 22-29
  作者：DIMMEL, D. R.、SHEPART, D.

  DOI：——

  日期：——